Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses
- Judit Szécsi1, 2, 3,
- Bertrand Boson1, 2, 3,
- Per Johnsson1, 2, 3,
- Pia Dupeyrot-Lacas1, 2, 3, 4,
- Mikhail Matrosovich5,
- Hans-Dieter Klenk5,
- David Klatzmann6,
- Viktor Volchkov1, 2, 3 and
- François-Loïc Cosset1, 2, 3Email author
© Szécsi et al. 2006
Received: 16 August 2006
Accepted: 03 September 2006
Published: 03 September 2006
There is an urgent need to develop novel approaches to vaccination against the emerging, highly pathogenic avian influenza viruses. Here, we engineered influenza viral-like particles (Flu-VLPs) derived from retroviral core particles that mimic the properties of the viral surface of two highly pathogenic influenza viruses of either H7N1 or H5N1 antigenic subtype. We demonstrate that, upon recovery of viral RNAs from a field strain, one can easily generate expression vectors that encode the HA, NA and M2 surface proteins of either virus and prepare high-titre Flu-VLPs. We characterise these Flu-VLPs incorporating the HA, NA and M2 proteins and we show that they induce high-titre neutralising antibodies in mice.
Influenza virus infects thousands of people each year, causing epidemics with severe mortality . Moreover, there is an increasing concern about a potential influenza pandemic, as highly virulent avian influenza strains are spreading from South-East Asia, with a high risk to cross species-specific barriers . With such a menace, we should be well prepared to prevent excessive mortality, should a virulent pandemic occur.
Vaccination, so far, has been the best manner to protect individuals from influenza infection. Influenza vaccines have been used for ca. 50 years . Current influenza vaccines are mostly inactivated formulations relying on the antigenic activity of the surface glycoproteins of influenza virus: a hemagglutinin (HA) and a neuraminidase (NA) . A major problem, when preparing an influenza vaccine, is the lack of cross-immunity generated against different influenza virus subtypes. This is due to the high mutagenic capacity of influenza virus to generate forms that can escape the immune system. Antigenic shifts and antigenic drifts are evolutionary mechanisms that lead to serologically different influenza virus subtypes or strains against which a vaccine is not efficient . Thus, new vaccines need to be prepared during each seasonal influenza epidemic and, importantly, there is no vaccine against the novel, emerging highly pathogenic viruses. Influenza vaccines are generally produced from virus grown in embryonated chicken eggs. This implies that manufacturing a vaccine preparation, from the appearance of a new sub-type of influenza virus until the readiness of the vaccine, takes several months . Moreover, one needs to modify the HA of highly virulent influenza strains in order to be able to produce vaccines without killing the embryos. Recently, reverse genetic methods have been used to produce vaccines in cell culture [6, 7]. Finally, in the event of a pandemic, the vaccine production has to be massive, quick and safe.
Altogether, there is a strong need for developing novel immunogenic formulations that can rapidly be prepared as vaccines against the emerging highly pathogenic avian influenza virus. As a step along this road, here we describe a novel influenza virus immunogen using engineered viral-like particles (Flu-VLPs) that mimic the properties of the viral surface of two highly pathogenic influenza viruses of H7N1 and H5N1 subtypes.
We used the surface proteins HA, NA and M2 of two highly pathogenic avian influenza viruses: A/Chicken/FPV/Rostock/1934 (H7N1)  and A/Thailand/KAN-1/04 (H5N1) [9, 10] to generate Flu-VLPs (H7-VLPs and H5-VLPs, respectively). The influenza hemagglutinin is responsible for virion attachment to the target cells through recognition and binding to terminal sialic acid groups on membrane-bound proteins of the host cell (reviewed in ). The neuraminidase destroys non-functional receptors to which hemagglutinin can bind and thus facilitates virus access to target cells at the early stages of infection and promotes egress of progeny viral particles from infected cells late in infection [12, 13]. M2 is a small transmembrane protein with an ion channel activity which regulates the pH inside the virion during viral entry into cell and protects newly synthesized acid-labile H5 and H7 hemagglutinins during their transport through low pH cellular compartments (reviewed in [14, 15]). Cloning of expression vectors for HA, NA and M2 from H7N1 virus has been described elsewhere [8, 16–19]. The human virus isolate of H5N1, A/Thailand/KAN-1/04 (H5N1) , was kindly provided by Pilaipan Puthavathana at Mahidol University, Bangkok, Thailand. We made one passage of the original seed virus in MDCK cells and isolated viral RNA using the High Pure RNA isolation kit (Roche Molecular Biochemicals, Mannheim, Germany). HA, NA and M2 coding sequences were then amplified from total viral RNA using Superscript Reverse transcriptase and specific primers (sequences are available upon request). PCR products were introduced into a CMV promoter-driven expression plasmid in a manner identical to that used for H7N1 .
The expression of M2 during Flu-VLP production did not influence the incorporation of HA or NA onto the viral particles (Fig. 1A). In contrast, only small amounts of HA proteins were detected on particles when NA was not co-expressed in producer cells, correlating with low quantities of MLV Gag-derived capsid (CA) proteins (Fig. 1A). This was most likely due to a less effective release of VLPs into the cell supernatant in the absence of NA. Indeed treatment of these latter cells with purified neuraminidase from Vibrio cholerae induced efficient release of the viral particles (data not shown). This confirmed the essential role of NA to promote the release virus particles from the cell surface by removing sialic acid receptors from producer cells [12, 26].
To estimate the concentration of Flu-VLPs, we determined their 'transduction titres' by adding serial dilutions of viral particle preparations harbouring a GFP marker gene to TE671 human rhabdomyosarcoma cells. The medium was then replaced with normal culture medium and the transduction titre was deduced 72 hr later from the percentage of GFP-positive cells measured by fluorescence-activated cell sorter (FACS) analysis, as previously described .
Interestingly, the transduction titres obtained with H7-VLPs were about 50-fold lower than those obtained with H5-VLPs (Fig. 1B). Furthermore, incorporation of M2 onto the Flu-VLPs increased the infectivity of H7-VLPs by about 10 times (Fig. 1B), as reported previously , but not that of H5-VLPs, as similar H5 HA incorporation levels were reached irrespective of whether or not M2 was expressed (Fig. 1A). This suggested that H7 HA, but not H5 HA, was sensitive to M2 functions. Consistent with its capacity to regulate the internal pH of endosomal compartments, the role of M2 during Flu-VLP production is probably to prevent acidification and premature activation of HA protein, an event for which H7N1 virus HA is apparently more sensitive than HA of H5N1 virus strain used in this study.
Altogether, these results indicated that HA, NA and M2 incorporated onto the surface of VLPs are functional as they efficiently mediate cell entry.
We then investigated whether Flu-VLPs harbouring all three viral proteins can induce specific immune responses and neutralising antibodies in mice. For these studies, H7-VLPs or H5-VLPs were concentrated and purified by ultracentrifugation  before injection in BalbC mice. Control VLPs, incorporating the VSV-G glycoprotein [17, 18], were also prepared and injected to mice in parallel. As an attempt to induce cross-neutralising antibodies against different influenza strains, we generated H7-VLPs or H5-VLPs treated with a citrate buffer at pH5.3 for 10 minutes. Indeed, at low pH, HA undergoes irreversible conformational changes that are required to induce membrane fusion . Such conformational changes alter the structure and antigenicity of HA [29, 30] and may result in exposure of conserved epitopes, hidden in the native HA conformation, that could induce cross-neutralising antibodies that are not raised otherwise, particularly in conserved regions of HA2 . Conformational changes were verified by demonstration of a complete loss of infectivity by low pH-treated particles (data not shown) .
About 108 particles of H7-VLPs or H5-VLPs, treated or non-treated at low pH, as well as VSV-VLPs particles were repeatedly injected intraperitoneally in 5 week-old female BalbC mice at 2 weeks intervals. The sera were harvested 2 weeks after each injections (harvests S1, S2, S3 and S4) and were decomplemented by heat inactivation at 56°C for 1 hr. We next determined the neutralising activity of the sera using the Flu-VLPs or the VSV-VLPs harbouring a GFP marker gene. The results of a typical experiment shown in Fig. 2A, are displayed as the % of neutralisation of the S2 sera compared to the S0 pre-immune sera, i.e., sera harvested before the first inoculation for each mouse, for a 1/100 dilution of these sera. Sera from mice injected with H7-VLPs neutralised specifically H7-VLPs, but neither the H5-VLPs nor the VSV-VLPs and vice-versa. Sera from mice injected with native Flu-VLPs neutralised more efficiently the homologous Flu-VLPs than sera from mice injected with acid pH-denatured Flu-VLPs; yet no cross-neutralisation was observed for the latter sera. Consistently, as tested on immunoblots of H7-VLPs vs. H5-VLPs, no cross-reactivity of H7- and H5-VLP sera could be observed for HA. Antibodies against M2 that detected M2 from either influenza virus strain were raised in some immunised mice (Fig. 2B), in agreement with the strong sequence homology between H7 M2 and H5 M2. No cross-reacting NA antibodies could be detected (Fig. 2B), perhaps owing to the relatively inefficient incorporation of this glycoprotein on the Flu-VLPs. Only few other non-specific protein bands were observed (Fig. 2B), suggesting that the antibody response against Flu-VLPs was specific. To investigate how the neutralising titres increased after repeated immunisations, we determined the titration curves for each serum harvest. The results are shown in Fig. 2C as the mean neutralisation values from sera of the different groups of mice. The neutralisation curves were similar for both H7 and H5 sera. We found that S1 sera, harvested 2 weeks after the first injection, had significant neutralising activity, with 50% neutralising activityreached at the 1/500 serum dilution and with an ID90 at the 1/100 dilution. The S2, S3 and S4 sera had much higher neutralising activities, even at high dilutions, with ID95 obtained at the 1/2,500 dilution for the S3 and/or S4 sera.
Altogether these results indicated that retroviral-derived VLPs incorporating HA, NA and M2 influenza proteins are able to induce antibody production in mice. Moreover, the immune response induced by these particles is rapid and robust, achieving efficient neutralisation only two weeks after the first injection. The produced antibodies are specific, as no cross-reaction between different influenza strains was observed. Such engineered Flu-VLPs, which can be prepared very rapidly as soon as influenza virus RNAs are isolated, could therefore provide a useful method to obtain in a timely manner a set of efficient immunological reagents such as sera, antibodies and influenza virus-like particles to study neutralisation in low containment laboratories.
Furthermore, we propose that Flu-VLPs that incorporate functional influenza virus surface proteins on defective retroviral core particles could provide a useful immunogenic formulation applicable as a vaccine. Such Flu-VLP can indeed be grown to high titres in mammalian or insect cell cultures to prepare vaccines in vitro , or, alternatively, could be secreted in vivo upon inoculation with plasmids  or viral vectors [33–35].
We thank Dr P. Puthavathana (Mahidol University, Bangkok, Thailand) for providing H5N1 influenza virus. We thank Drs W. Garten, R.G. Webster and A. Hay for providing antibodies and sera against H7N1 and H5N3 influenza virus surface proteins. We thank the personals from the animal facility "PBES" of the Ecole Normale Supérieure de Lyon.
This work was supported by the European Community (contract LSHB-CT-2004-005246 "COMPUVAC"), the Région Rhône-Alpes (FITT 2005) and the Agence Nationale pour la Recherche (ANR "MIME").
- Nicholson KG, Wood JM, Zambon M: Influenza. Lancet 2003, 362:1733–1745.View ArticlePubMed
- Webby RJ, Webster RG: Are we ready for pandemic influenza? Science 2003, 302:1519–1522.View ArticlePubMed
- Francis TJ: Vaccination against influenza. Bull World Health Organ 1953, 8:725–741.PubMed
- Hilleman MR: Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 2002, 20:3068–3087.View ArticlePubMed
- Tamura S, Tanimoto T, Kurata T: Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 2005, 58:195–207.PubMed
- Check E: Avian flu special: is this our best shot? Nature 2005, 435:404–406.View ArticlePubMed
- Hoffmann E, Krauss S, Perez D, Webby R, Webster RG: Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 2002, 20:3165–3170.View ArticlePubMed
- Ohuchi M, Cramer A, Vey M, Ohuchi R, Garten W, Klenk HD: Rescue of vector expressed fowl plague virus hemagglutinin in biologically active form by acidotropic agents and coexpressed M2 protein. J Virol 1994, 68:920–926.PubMed
- Puthavathana P, Auewarakul P, Charoenying PC, Sangsiriwut K, Pooruk P, Boonnak K, Khanyok R, Thawachsupa P, Kijphati R, Sawanpanyalert P: Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand. J Gen Virol 2005, 86:423–433.View ArticlePubMed
- Amonsin A, Payungporn S, Theamboonlers A, Thanawongnuwech R, Suradhat S, Pariyothorn N, Tantilertcharoen R, Damrongwantanapokin S, Buranathai C, Chaisingh A, Songserm T, Poovorawan Y: Genetic characterization of H5N1 influenza A viruses isolated from zoo tigers in Thailand. Virology 2006, 344:480–491.View ArticlePubMed
- Skehel JJ, Wiley DC: Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000, 69:531–569.View ArticlePubMed
- Bucher D, Palese P: The biologically active proteins of influenza virus: neuraminidase. The influenza viruses and influenza (Edited by: Kilbourne ED). New York, Academic Press 1975, 83–123.
- Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD: Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 2004, 78:12665–12667.View ArticlePubMed
- Lamb RA, Holsinger LJ, Pinto LH: The influenza A virus M2 ion channel protein and its role in the influenza virus life cycle. Cellular receptors of animal viruses (Edited by: Wimmer E). Cold Spring Harbor, Cold Spring Harbor Laboratory 1994, 303–321.
- Hay AJ: The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel protein. Semin Virol 1992, 3:21–30.
- Hatziioannou T, Valsesia-Wittmann S, Russell SJ, Cosset FL: Incorporation of fowl plague virus hemagglutinin into murine leukemia virus particles and analysis of the infectivity of the pseudotyped retroviruses. J Virol 1998, 72:5313–5317.PubMed
- Sandrin V, Boson B, Salmon P, Gay W, Nègre D, LeGrand R, Trono D, Cosset FL: Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and non-human primates. Blood 2002, 100:823–832.View ArticlePubMed
- Sandrin V, Cosset FL: Intracellular versus cell surface assembly of retroviral pseudotypes is determined by the cellular localization of the viral glycoprotein, its capacity to interact with Gag, and the expression of the Nef protein. J Biol Chem 2006, 281:528–542.View ArticlePubMed
- Szecsi J, Drury R, Josserand V, Grange MP, Boson B, Hartl I, Schneider R, Buchholz C, Coll JL, Russell SJ, Cosset FL, Verhoeyen E: Targeted retroviral vectors displaying a cleavage site-engineered hemagglutinin (HA) through HA-protease interactions. Mol Ther 2006., in press:
- Bellier B, Dalba C, Clerc B, Desjardins D, Drury R, Cosset FL, Collins M, Klatzmann D: DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine 2006, 24:2643–2655.View ArticlePubMed
- Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli E, Cortese R, Nicosia A, Cosset FL: Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 2003, 278:41624–41630.View ArticlePubMed
- Negre D, Mangeot PE, Duisit G, Blanchard S, Vidalain PO, Leissner P, Winter AJ, Rabourdin-Combe C, Mehtali M, Moullier P, Darlix JL, Cosset FL: Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. Gene Ther 2000, 7:1613–1623.View ArticlePubMed
- Bartosch B, Dubuisson J, Cosset FL: Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003, 197:633–642.View ArticlePubMed
- Bartosch B, Bukh J, Meunier JC, Granier C, Engle RE, Blackwelder WC, Emerson SU, Cosset FL, Purcell RH: In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A 2003, 100:14199–14204.View ArticlePubMed
- Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, Pagkalos E, Sakellariou G, Intrator L, Bartosch B, Pawlotsky JM, Cosset FL: Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 2005, 79:6023–6034.View ArticlePubMed
- Bosch V, Kramer B, Pfeiffer T, Starck L, Steinhauer DA: Inhibition of release of lentivirus particles with incorporated human influenza virus haemagglutinin by binding to sialic acid-containing cellular receptors. J Gen Virol 2001, 82:2485–2494.PubMed
- McKay T, Patel M, Pickles RJ, Johnson LG, Olsen JC: Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors. Gene Ther 2006, 13:715–724.View ArticlePubMed
- Skehel JJ, Bayley PM, Brown EB, Martin SR, Waterfield MD, White JM, Wilson IA, Wiley DC: Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion. Proc Natl Acad Sci U S A 1982, 79:968–972.View ArticlePubMed
- Graves PN, Schulman JL, Young JF, Palese P: Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. Virology 1983, 126:106–116.View ArticlePubMed
- Sagawa H, Ohshima A, Kato I, Okuno Y, Isegawa Y: The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region. J Gen Virol 1996, 77 ( Pt 7):1483–1487.View Article
- Okuno Y, Isegawa Y, Sasao F, Ueda S: A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 1993, 67:2552–2558.PubMed
- Yao Q, Kuhlmann FM, Eller R, Compans RW, Chen C: Production and characterization of simian--human immunodeficiency virus-like particles. AIDS Res Hum Retroviruses 2000, 16:227–236.View ArticlePubMed
- Duisit G, Salvetti A, Moullier P, Cosset FL: Functional characterization of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines. Human Gene Therapy 1999, 10:189–200.View ArticlePubMed
- Roberts ML, Wells DJ, Graham IR, Fabb SA, Hill VJ, Duisit G, Yuasa K, Takeda S, Cosset FL, Dickson G: Stable micro-dystrophin gene transfer using an integrating adeno-retroviral hybrid vector ameliorates the dystrophic pathology in mdx mouse muscle. Hum Mol Genet 2003, 11:1719–1730.View Article
- Savard N, Cosset FL, Epstein AL: Use of defective HSV-1 vectors harbouring gag, pol, and env genes to rescue defective retrovirus vectors. J Virol 1997, 71:4111–4117.PubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.